Funding Round for Biotech Start-Up Abolis By L'Oreal and Evonik

Thursday, 12 September 2024, 09:22

Funding highlights the growing interest in biotechnology, with L'Oreal and Evonik investing in Abolis. The $38.6 million funding is aimed at enhancing research into micro-organisms. Abolis is positioned in the Genopole, a key biotechnology hub in France.
LivaRava_Medicine_Default.png
Funding Round for Biotech Start-Up Abolis By L'Oreal and Evonik

Funding Round Announcement

Abolis, a French start-up specializing in biotechnology, recently secured a significant funding round of $38.6 million. This funding was prominently supported by major industry players L'Oreal and Evonik, reflecting a broader trend towards investing in innovative biotech solutions.

About Abolis

Located in the Genopole in Evry, south of Paris, Abolis leverages micro-organisms for various applications. Since its inception in 2014, the company has raised a total of $1.1 million to date, demonstrating commitment towards sustainable and innovative biological research.

Future Implications

  • This funding marks a crucial step for Abolis in expanding its research capabilities.
  • It emphasizes the increasing relevance of biotech start-ups in addressing modern challenges.
  • The involvement of industry giants like L'Oreal and Evonik adds credibility and resources to Abolis's mission.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe